{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:14:20Z","timestamp":1776244460801,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10072-026-08933-5","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:25:43Z","timestamp":1773109543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of deferiprone for Parkinson\u2019s disease: a systematic review and meta-analysis of motor function and overall disease severity"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8181","authenticated-orcid":false,"given":"Ismail A.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-4413","authenticated-orcid":false,"given":"Mandy","family":"Elewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0761-6772","authenticated-orcid":false,"given":"Israa A.","family":"Solah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5826-0423","authenticated-orcid":false,"given":"Moaz","family":"Ezz-Alarab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6305-6020","authenticated-orcid":false,"given":"Rawan Gameel","family":"Hekal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7254-6659","authenticated-orcid":false,"given":"Menna","family":"Ehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-6906","authenticated-orcid":false,"given":"Amro K.","family":"AlQurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3004-6347","authenticated-orcid":false,"given":"Rahma M.","family":"Almetwaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1137-0970","authenticated-orcid":false,"given":"Ayham R. A.","family":"Zidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"11","key":"8933_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC et al (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939\u2013953. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3","journal-title":"Lancet Neurol"},{"issue":"4","key":"8933_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/mds.29362","volume":"38","author":"M Bologna","year":"2023","unstructured":"Bologna M, Espay AJ, Fasano A, Paparella G, Hallett M, Berardelli A (2023) Redefining bradykinesia. Mov disorders: official J Mov Disorder Soc 38(4):551","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"3 Suppl","key":"8933_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ncl.2013.04.013","volume":"31","author":"VW Sung","year":"2013","unstructured":"Sung VW, Nicholas AP (2013) Nonmotor symptoms in Parkinson\u2019s disease: expanding the view of Parkinson\u2019s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin 31(3 Suppl):S1\u201316. https:\/\/doi.org\/10.1016\/j.ncl.2013.04.013","journal-title":"Neurol Clin"},{"key":"8933_CR4","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"8933_CR5","first-page":"257","volume":"5","author":"DD Webster","year":"1968","unstructured":"Webster DD (1968) Critical analysis of the disability in Parkinson\u2019s disease. Mod Treat 5(2):257\u2013282","journal-title":"Mod Treat"},{"issue":"3","key":"8933_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ana.410030314","volume":"3","author":"SG Diamond","year":"1978","unstructured":"Diamond SG, Markham CH, Treciokas LJ (1978) A double-blind comparison of levodopa, madopa, and sinemet in Parkinson disease. Ann Neurol 3(3):267\u2013272. https:\/\/doi.org\/10.1002\/ana.410030314","journal-title":"Ann Neurol"},{"issue":"15","key":"8933_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"5","key":"8933_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/biom12050714","volume":"12","author":"P Dusek","year":"2022","unstructured":"Dusek P, Hofer T, Alexander J, Roos PM, Aaseth JO (2022) Cerebral iron deposition in neurodegeneration. Biomolecules 12(5):714. https:\/\/doi.org\/10.3390\/biom12050714","journal-title":"Biomolecules"},{"issue":"10","key":"8933_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045\u20131060. https:\/\/doi.org\/10.1016\/S1474-4422(14)70117-6","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"8933_CR10","doi-asserted-by":"publisher","first-page":"S551","DOI":"10.3233\/JAD-2010-100354","volume":"20","author":"MP Horowitz","year":"2010","unstructured":"Horowitz MP, Greenamyre JT (2010) Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis 20(Suppl 2):S551\u2013S568. https:\/\/doi.org\/10.3233\/JAD-2010-100354","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"8933_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/BF02252926","volume":"2","author":"K Jellinger","year":"1990","unstructured":"Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson\u2019s and Alzheimer\u2019s diseases. J Neural Transm Park Dis Dement Sect.\u00a0 2(4):327\u2013340. https:\/\/doi.org\/10.1007\/BF02252926","journal-title":"J Neural Transm Park Dis Dement Sect"},{"issue":"Suppl 1","key":"8933_CR12","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1016\/S1353-8020(11)70057-8","volume":"18","author":"V Jackson-Lewis","year":"2012","unstructured":"Jackson-Lewis V, Blesa J, Przedborski S (2012) Animal models of Parkinson\u2019s disease. Parkinsonism Relat Disord 18(Suppl 1):S183\u2013S185. https:\/\/doi.org\/10.1016\/S1353-8020(11)70057-8","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"8933_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2450\/2012.0008-12","volume":"10","author":"E Poggiali","year":"2012","unstructured":"Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD (2012) An update on iron chelation therapy. Blood Transfus 10(4):411\u2013422. https:\/\/doi.org\/10.2450\/2012.0008-12","journal-title":"Blood Transfus"},{"issue":"4","key":"8933_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/ph11040109","volume":"11","author":"MT Nu\u00f1ez","year":"2018","unstructured":"Nu\u00f1ez MT, Chana-Cuevas P (2018) New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. Pharmaceuticals (Basel) 11(4):109. https:\/\/doi.org\/10.3390\/ph11040109","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"8933_CR15","doi-asserted-by":"publisher","first-page":"e14607","DOI":"10.1111\/cns.14607","volume":"30","author":"A Negida","year":"2024","unstructured":"Negida A, Hassan NM, Aboeldahab H, Zain YE, Negida Y, Cadri S et al (2024) Efficacy of the iron-chelating agent deferiprone in patients with Parkinson\u2019s disease: a systematic review and meta-analysis. CNS Neurosci Ther 30(2):e14607. https:\/\/doi.org\/10.1111\/cns.14607","journal-title":"CNS Neurosci Ther"},{"key":"8933_CR16","doi-asserted-by":"publisher","first-page":"e48276","DOI":"10.7759\/cureus.48276","volume":"15","author":"A Salem","year":"2023","unstructured":"Salem A, Desai P, Elgebaly A (2023) Efficacy and safety of combined deferiprone and deferasirox in iron-overloaded patients: a systematic review. Cureus 15:e48276. https:\/\/doi.org\/10.7759\/cureus.48276","journal-title":"Cureus"},{"issue":"9","key":"8933_CR17","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/mds.29145","volume":"37","author":"F Marchand","year":"2022","unstructured":"Marchand F, Moreau C, Kuchcinski G, Huin V, Defebvre L, Devos D (2022) Conservative iron chelation for neuroferritinopathy. Mov Disord 37(9):1948\u20131952. https:\/\/doi.org\/10.1002\/mds.29145","journal-title":"Mov Disord"},{"issue":"7","key":"8933_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","volume":"18","author":"T Klopstock","year":"2019","unstructured":"Klopstock T, Tricta F, Neumayr L et al (2019) Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol 18(7):631\u2013642. https:\/\/doi.org\/10.1016\/S1474-4422(19)30142-5","journal-title":"Lancet Neurol"},{"issue":"8","key":"8933_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1177\/0883073816636087","volume":"31","author":"S Elincx-Benizri","year":"2016","unstructured":"Elincx-Benizri S, Glik A, Merkel D et al (2016) Clinical experience with deferiprone treatment for Friedreich ataxia. J Child Neurol 31(8):1036\u20131040. https:\/\/doi.org\/10.1177\/0883073816636087","journal-title":"J Child Neurol"},{"issue":"2","key":"8933_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal 21(2):195\u2013210. https:\/\/doi.org\/10.1089\/ars.2013.5593","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"8933_CR21","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo-controlled clinical trial in Parkinson\u2019s disease. Sci Rep 7(1):1398. https:\/\/doi.org\/10.1038\/s41598-017-01402-2","journal-title":"Sci Rep"},{"issue":"22","key":"8933_CR22","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos D, Labreuche J, Rascol O et al (2022) Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med 387(22):2045\u20132055. https:\/\/doi.org\/10.1056\/NEJMoa2209254","journal-title":"N Engl J Med"},{"key":"8933_CR23","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"8933_CR24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"8933_CR25","unstructured":"PROSPERO: International prospective register of systematic reviews. York: University of York (2023) Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/"},{"key":"8933_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"8933_CR27","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"1","key":"8933_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1877718X241300295","volume":"15","author":"D Devos","year":"2025","unstructured":"Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, Anheim M, Malt\u00eate D, Remy P, Eggert K, Pape H (2025) Therapeutic modalities of deferiprone in Parkinson\u2019s disease: SKY and EMBARK studies. J Parkinson\u2019s Disease 15(1):72\u201386","journal-title":"J Parkinson\u2019s Disease"},{"issue":"6","key":"8933_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/iub.1616","volume":"69","author":"S Doll","year":"2017","unstructured":"Doll S, Conrad M (2017) Iron and ferroptosis: a still ill-defined liaison. IUBMB Life 69(6):423\u2013434. https:\/\/doi.org\/10.1002\/iub.1616","journal-title":"IUBMB Life"},{"issue":"7","key":"8933_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","volume":"92","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92(7):329\u2013337","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08933-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08933-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:39:30Z","timestamp":1776242370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08933-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["8933"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08933-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}